| ADRB1 | |
|---|---|
| Full Name | Beta-1 Adrenergic Receptor |
| Gene Symbol | ADRB1 |
| Chromosomal Location | 10q25.3 |
| NCBI Gene ID | 153 |
| OMIM ID | 109630 |
| Ensembl ID | ENSG00000143578 |
| UniProt ID | P08588 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Heart Failure, Hypertension, Depression |
ADRB1 encodes the β1-adrenergic receptor (β1-AR), a G-protein coupled receptor (GPCR) that mediates the effects of endogenous catecholamines epinephrine and norepinephrine. As the primary receptor governing cardiac sympathetic responses, β1-AR plays crucial roles in regulating heart rate, myocardial contractility, and blood pressure. In the central nervous system, β1-AR is expressed in key regions involved in cognition, arousal, and autonomic regulation, making it relevant to neurodegenerative diseases including Alzheimer's disease and Parkinson's disease[1][2].
The β1-AR belongs to the adrenergic receptor family (ADRA1, ADRA2, ADRB), all of which are class A GPCRs. It primarily couples to Gs proteins, stimulating adenylyl cyclase activity and increasing intracellular cAMP levels, leading to activation of protein kinase A (PKA) and downstream phosphorylation of target proteins[3].
The ADRB1 gene is located on chromosome 10q25.3 and spans approximately 2.4 kilobases. It consists of a single exon encoding a 477-amino acid protein, making it one of the simplest GPCR genes. The promoter region contains several transcription factor binding sites including:
This promoter architecture enables tissue-specific expression and dynamic regulation in response to physiological demands[@bork2002].
The β1-adrenergic receptor has classical GPCR architecture:
The ligand-binding pocket is formed by the transmembrane domains and recognizes catecholamines with a characteristic catechol ring structure. The binding affinity for epinephrine and norepinephrine is in the nanomolar range[1:1].
Upon agonist binding, β1-AR undergoes a conformational change that activates the associated Gs protein:
Beyond the classical cAMP/PKA pathway, β1-AR activates:
These pathways are particularly relevant to neuronal survival and neuroprotection[4][5].
β1-AR is subject to multiple regulatory mechanisms:
These regulatory mechanisms have important implications for therapeutic interventions.
β1-adrenergic signaling has complex and context-dependent effects in AD:
The noradrenergic system from the locus coeruleus modulates attention, memory formation, and arousal. β1-AR activation enhances memory consolidation through the cAMP/PKA/CREB pathway in the hippocampus[6]:
β1-AR density decreases with normal aging and is further reduced in AD, contributing to cognitive deficits. Postmortem studies show significant loss of β1-AR binding in the frontal cortex and hippocampus of AD patients[7].
β1-AR signaling can modulate amyloid precursor protein (APP) processing:
However, chronic β1-AR overstimulation may also exacerbate pathology through increased calcium influx and oxidative stress. The relationship is complex and may depend on disease stage[8].
The noradrenergic system has potent anti-inflammatory effects:
This anti-inflammatory property makes β1-AR a potential therapeutic target. However, the blood-brain barrier limits peripheral drug access to CNS β1-AR[9][5:1].
Several studies have examined ADRB1 polymorphisms in AD risk:
One of the hallmark pathologies in PD is cardiac sympathetic denervation:
This denervation leads to supersensitivity of remaining β1-AR as a compensatory mechanism. The functional consequences for PD progression remain an area of active investigation[12].
β1-AR activation may protect dopaminergic neurons:
Interestingly, epidemiological studies have shown that β-blocker use is associated with reduced PD risk, though confounding factors complicate interpretation[13][14][15].
β1-AR may influence levodopa-induced dyskinesias (LID):
This remains controversial and requires further investigation[16].
β1-AR activation provides neuroprotection in ischemic stroke:
The noradrenergic system is a key target in depression:
In the brain, β1-AR is expressed in:
Highest peripheral expression is in:
β1-AR is a major drug target for cardiovascular disease:
| Drug Class | Examples | Clinical Use | Mechanism |
|---|---|---|---|
| β1-selective blockers | Metoprolol, Atenolol, Bisoprolol | Hypertension, heart failure, arrhythmia | ↓ Heart rate, ↓ contractility |
| Non-selective β-blockers | Propranolol, Nadolol | Hypertension, anxiety, portal hypertension | Blocks β1 and β2 |
| β1-selective agonists | Dobutamine | Acute heart failure | ↑ Contractility |
| Combined α/β blockers | Carvedilol | Heart failure, hypertension | Vasodilation + ↓ contractility |
Several approaches are being explored:
Bcl2 knockout mice exhibit:
β1-AR modulators have been tested in:
Brodde OE. Beta-1 and beta-2 adrenergic receptors: distribution and function in the immune system. Pharmacology and Therapeutics. 2008. ↩︎ ↩︎ ↩︎
Zuo L, et al. Beta-adrenergic signaling in neurodegenerative diseases. Neuroscience Bulletin. 2020. ↩︎ ↩︎
Lefkowitz RJ, et al. Historical review: the discovery of beta-adrenergic receptors. Molecular Pharmacology. 2000. ↩︎ ↩︎
Wang J, et al. Beta1-adrenergic receptor modulates mitochondrial function and oxidative stress in neurons. Redox Biology. 2021. ↩︎ ↩︎
Varghese M, et al. Neuroinflammation and beta-adrenergic signaling in neurodegenerative disorders. Frontiers in Cellular Neuroscience. 2022. ↩︎ ↩︎ ↩︎
Li S, et al. The role of beta-adrenergic signaling in memory and cognitive function. Neuropsychopharmacology. 2018. ↩︎ ↩︎
Tong H, et al. Beta-adrenergic receptors in the cerebral cortex in AD and aging. Journal of Neural Transmission. 2016. ↩︎
Jiang W, et al. Beta-adrenergic receptor signaling in Alzheimer's disease. Journal of Alzheimer's Disease. 2017. ↩︎ ↩︎
Yuan M, et al. Beta-adrenergic modulation of neuroinflammation in AD models. Brain Research Bulletin. 2019. ↩︎ ↩︎
Park K, et al. Genetic variation in ADRB1 and susceptibility to Alzheimer's disease. Journal of Gerontology. 2017. ↩︎
Ross OA, et al. Association between beta-adrenergic receptor polymorphisms and neurodegenerative disease. Molecular Neurobiology. 2015. ↩︎
Liu X, et al. Cardiac sympathetic denervation in Parkinson's disease: role of beta-adrenergic receptors. Neurology. 2020. ↩︎ ↩︎
Yang K, et al. Beta-blocker use and risk of Parkinson's disease: a meta-analysis. Neurobiology of Aging. 2018. ↩︎ ↩︎
Romas SN, et al. Beta-adrenergic receptor blockers and Parkinson's disease progression. Movement Disorders. 2013. ↩︎ ↩︎
Chen Z, et al. Beta1-adrenergic receptor activation ameliorates alpha-synuclein toxicity. Journal of Parkinson's Disease. 2019. ↩︎ ↩︎
Zhang Y, et al. Beta1-adrenergic receptor agonists as potential neuroprotective agents for PD. CNS Drugs. 2019. ↩︎